ClinicalTrials.gg
Status unknownNCT03381755Updated Sep 12, 2018

Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI

A Phase 4 interventional study of half-dose ticagrelor and standard-dose ticagrelor in Acute Coronary Syndrome, sponsored by First Affiliated Hospital of Harbin Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-12.

Sponsored by First Affiliated Hospital of Harbin Medical University · Phase 4, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 185 studies in Acute Coronary Syndrome with a site in China — 56 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Planned enrollment
78th of 115
200 · median 499
Started
2018
with 12 others
Phase 4
47 of 185
12 open now
Registered
69th of 185
by date

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 78th largest by planned enrollment of the 115 interventional ones that give a count, is one of 13 that started in 2018, is one of 47 in phase 4, and was the 69th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

56 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor.

Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But the effectiveness and safety of low-dose ticagrelor remain yet not very clearly in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • After half-dose ticagrelor (loading dose 90mg, and then 45mg bidpo.) treatment for 3 days, the aggregation is effectively inhibited by light transmission aggregometry method and thromboela-stogram.
  • planned to undergo PCI recently
  • planned to DAPT for 1 year after PCI

Exclusion criteria

Exclusion Criteria:

  • taken adenosine diphosphate (ADP) receptor antagonists within 2 weeks
  • count \<100g/L;
  • A history of bleeding tendency;
  • Aspirin, ticagrelor or clopidogrel allergies;
  • Severe liver injury.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    half-dose ticagrelor

    Drug: half-dose ticagrelor

  • Active comparator
    standard-dose ticagrelor

    Drug: standard-dose ticagrelor

Interventions

  • Drughalf-dose ticagrelor

    To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.

  • To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.

06

What researchers measure

Primary outcomes

  1. thromboela-stogram

    inhibition of platelet aggregation (ADP) ; MA (ADP)

    Time frame: up to 6 months

  2. thromboela-stogram

    inhibition of platelet aggregation; MA

    Time frame: up to 1 year

Secondary outcomes

  1. MACE

    cardiovascular death, non-fatal myocardial infarction and stroke

    Time frame: up to 1 year

  2. Side effects including bleeding and dyspnea

    Time frame: up to 1 year

  3. The rate of treatment interruption due to ticagrelor intolerance.

    Time frame: up to 1 year

07

Study locations

1 of 1 sites recruiting
  • Thromboela-Stogram
    Beijing, Beijing 100001, China
    Recruiting
    • Liu Yang, MM · Contact86-010-801231171
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2019, 23 months after the start.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 23 months is below that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Dec 22, 2017
StartActual
Jan 1, 2018
Primary completionEst.
Dec 14, 2019
CompletionEst.
Dec 14, 2020
Last update
Sep 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03381755
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Responsible party
Sponsor
First posted
Dec 22, 2017
Start date
Jan 1, 2018
Primary completion
Dec 14, 2019 (estimated)
Completion
Dec 14, 2020 (estimated)
Last update
Sep 12, 2018

Study contacts

Guangzhong Liu, PhD
Contact
lgz2700@126.com
86-451-85555673
Yue Li, PhD
principal investigator · Cardiovascular Department, the First Affiliated Hospital of Harbin Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion